Bortezomib-Induced Complete Heart Block and Myocardial Scar: The Potential Role of Cardiac Biomarkers in Monitoring Cardiotoxicity

Bortezomib is a proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. Traditionally, bortezomib was thought to have little cardiovascular toxicity; however, there is increasing evidence that bortezomib can lead to cardiac complications including left ventricular dysfunction a...

Descripción completa

Detalles Bibliográficos
Autores principales: Diwadkar, Sachin, Patel, Aarti A., Fradley, Michael G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2016
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4749759/
https://www.ncbi.nlm.nih.gov/pubmed/26942019
http://dx.doi.org/10.1155/2016/3456287

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4749759/
https://www.ncbi.nlm.nih.gov/pubmed/26942019
http://dx.doi.org/10.1155/2016/3456287

Ejemplares similares